Drug addiction is a serious problem worldwide. One therapy being investigated is vaccines against drugs of abuse. The antibodies elicited against the drug can take up the drug and prevent it from reaching the reward centers in the brain. Few such vaccines have entered clinical trials, but research is going on apace. Many studies are very promising and more clinical trials should be coming out in the near future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063243 | PMC |
| http://dx.doi.org/10.1177/2051013614537818 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potent antiviral action detected in extracts against .
Drug Dev Ind Pharm
January 2025
Laboratory of Virology and Cellular Technology, Department of Chemistry, Biotechnology, and Bioprocess Engineering, Universidade Federal de São João del-Rei, Ouro Branco, MG, Brazil.
Background: , a notable plant species, has garnered interest for its medicinal properties, including anti-inflammatory, antibacterial and antiviral effects. A vaccine for Chikungunia virus is still under evaluation and no specific antiviral drug has been licensed to date.
Objective: The work investigated antiviral activity of ethyl acetate (EAEF) and methanolic (EMF) extracts from leaves in mammalian cells exposed to (CHIKV).
Length of hospital stay not affected by empirical treatment with ceftriaxone versus cefuroxime for bacteraemia.
Acta Paediatr
January 2025
Pediatric Department, Laniado Hospital, Netanya, Israel.
Aim: The preferred antibiotic treatment for bacteraemia in infants continues to be debated. We examined the duration of hospital stays as a surrogate for the effectiveness of initial treatment with ceftriaxone versus cefuroxime.
Methods: This was a retrospective review of the medical records of all infants aged 3-36 months, admitted with suspected occult bacteraemia to the paediatric department at Laniado Hospital, Israel, between 2016 and 2022.
Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures.
Vaccine
January 2025
Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address:
In recent years, human mpox has made multiple resurges, prompting public health professionals to consider factors that lead to the increased risk for the reemergence of other orthopoxviruses. Due to the genetic similarity between orthopoxviruses, vaccinia vaccines used to prevent smallpox transmission are also indicated and have been used for mpox infection prevention and control. In this study, cross-reactive immunity for mpox was observed among individuals with self-reported history of smallpox vaccination.
View Article and Find Full Text PDFFcRn-guided antigen trafficking enhances cancer vaccine efficacy.
Cancer Immunol Immunother
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.
The development of tumor vaccines represents a significant focus within cancer therapeutics research. Nonetheless, the efficiency of antigen presentation in tumor vaccine remains suboptimal. We introduce an innovative mRNA-lipid nanoparticle platform designed to express tumor antigenic epitopes fused with the transmembrane domain and cytoplasmic tail of the neonatal Fc receptor (FcRn).
View Article and Find Full Text PDFGenetic variability in snake venom and its implications for antivenom development in sub-Saharan Africa.
Trans R Soc Trop Med Hyg
January 2025
Pharm-Biotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Faculty of Medicine, Mbarara University of Science and Technology, Mbarara 40006, Uganda.
Snake venom, a complex mixture of proteins, has attracted human attention for centuries due to its associated mortality, morbidity and other therapeutic properties. In sub-Saharan Africa (SSA), where snakebites pose a significant health risk, understanding the genetic variability of snake venoms is crucial for developing effective antivenoms. The wide geographic distribution of venomous snake species in SSA countries demonstrates the need to develop specific and broad antivenoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!